Exhibit
10-AR


AGREEMENT FOR
CHANGE-OF-CONTROL BENEFIT


This Agreement for
Change-of-Control Benefit (the “Agreement”) is entered into effective September
5, 2006 and January 2, 2007 (the “Effective Date”) between Thomas Lawlor,
President, Patient Division and Christopher Lindop, Vice President and Chief
Financial Officer, respectively, who is a member of the Haemonetics Corporation
Operating Committee (the “Executive”), and who resides at            (intentionally
blank contained in each original) , and Haemonetics Corporation (the “Company”),
a Massachusetts corporation with its principal executive offices at 400 Wood
Road, Braintree, Massachusetts 02184.


For so long as Executive
remains a member of the Company’s Operating Committee, then


1. If, following a “Change
of Control” (as defined below), Executive’s full time position with the Company
is eliminated or permanently transferred to a location other than its present
location, and following such elimination or transfer, the Company does not
offer to employ Executive in a comparable or better position in Executive’s
current location, on a full-time basis, at a comparable or better rate of pay,
then Executive shall be considered to have been constructively terminated and
shall be entitled to a severance payment and benefits as provided  below.


 2. For purposes of this Agreement, a “Change
of Control” shall mean a change of control of the Company of a nature that
would be required to be reported in response to Item 6(e) of Schedule 14A of
Regulation 14A promulgated under the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), whether or not the Company is, in fact, required
to comply therewith; provided that, without limitation, such a Change of
Control for purposes of this Agreement shall be deemed to have occurred if:


(i)       any “person” (as such term is used in
Sections 13(d) and 14(d) of the Exchange Act), other than the Company, any
trustee or other fiduciary holding securities under an employee benefit plan of
the Company or a corporation owned, directly or indirectly, by the stockholder
of the Company in substantially the same proportions as their ownership of
stock of the Company is or becomes the “beneficial owner” (as defined in Rule
13d-3 under the Exchange Act), directly or indirectly, of securities of the
Company representing 51% or more of the combined voting power of the Company’s
then outstanding securities;


(ii)      the stockholders of the Company approve a
merger or consolidation of the Company with any other corporation, other than
(A) a merger or consolidation which would result in the voting securities of
the Company outstanding immediately prior thereto continuing to represent
(either by remaining outstanding or by being converted into voting securities
of the surviving entity) at least 50% of the combined voting securities of the
Company or such surviving entity outstanding immediately after such merger or
consolidation, or (B) a merger or consolidation effected to implement a
recapitalization of the Company (or similar transaction) in which no “person”
(as herein above defined) acquires 50% or more of the combined voting power of
the Company’s then outstanding securities; or


(iii)     the stockholders of the Company approve a
plan of complete liquidation of the Company or an agreement for the sale or
disposition by the Company of all or substantially all of the Company’s assets.


3. Upon termination, a
severance payment shall be paid to Executive, in lump sum, in an amount which
equals 2 times the Executive’s then current annualized Base Salary and target
bonus.


4. To the extent
permitted by law and applicable insurance policies or plans, the Company shall
allow Executive to continue to participate in the Company’s medical and dental
plans for a period of twelve months from termination of employment, at employee
contribution rates applicable to other Company employees of the same coverage
election, provided however that as to U.S. based Executives, to the full extent
permitted by law, such continued participation in the Company’s medical and dental
plan shall satisfy twelve months of the Executive’s rights to any COBRA
benefit. If continuation of health care coverage is not permitted, then the
Company shall pay Executive the cash value of substantially equivalent health
care benefits received by Executive prior to the Change of Control.


5. The Company shall
provide to Executive substantially equivalent benefits or, at Executive’s
election, the cash 











value of substantially
equivalent benefits provided by Company’s life insurance and disability insurance
policies, for a period of twelve months from termination of employment, at
employee contribution rates applicable to other Company employees of the same
coverage election.


6.  In the event it shall be determined that any
payment(s) or distribution(s) by the Company to or for the Executive’s benefit
(whether paid or payable or distributed or distributable pursuant to the terms
of this Agreement or otherwise, but determined without regard to any additional
payments required under this provision) (collectively, a “Payment”) would be
subject to the excise tax imposed by Section 4999 of the Internal Revenue Code
(including any succeeding provision) and/or any regulations, or any interest or
penalties are incurred by the Executive with respect to such excise tax (such
excise tax, together with any such interest and penalties, are hereinafter
collectively referred to as the “Excise Tax”), then the Executive shall be
entitled to receive an additional payment (a “Gross-Up Payment”) in an amount
such that after payment by the Executive of all taxes, including, without
limitation, any income taxes (and any interest and penalties imposed with
respect thereto) and Excise Tax imposed upon the Gross-Up Payment, the
Executive shall retain an amount of the Gross-Up Payment equal to the Excise
Tax (including any interest or penalties imposed with respect to such taxes)
imposed upon the Payment.  The Executive
shall cooperate with the Company in providing information concerning Executive’s
personal federal, state and local income tax rate reasonably needed by the
Company to calculate the Gross-Up Payment.


7. The benefits provided
herein shall supercede any prior arrangement on Change of Control benefits
contained in any written employment agreement between the Executive individually
and the Company, but shall not supercede such benefits under other
arrangements, including (but not limited to) accelerated vesting of benefits
under any equity compensation arrangements of the Company.  To the extent that such benefits are superceded
in any such written employment agreement, the remaining terms of such
employment agreement shall remain in full force and effect.  Nothing herein shall constitute an agreement
to offer employment or maintain employment of Executive.


8. Executive shall serve
on the Company’s Operating Committee at the exclusive discretion of the
President and CEO, and nothing herein shall constitute an agreement to maintain
Executive’s membership on the Operating Committee.


9. This Agreement may not
be amended except in a written instrument, signed by both parties.


IN WITNESS WHEREOF, the
undersigned have duly executed and delivered this Agreement under seal as of
the date first above written.


	
  HAEMONETICS CORPORATION

  
	
  By:

  
	
   

  
	
   

  
	
  Brad Nutter

  
	
  President and
  CEO

  
	
  Date:

  
	
   

  
	
  EXECUTIVE

  
	
   

  
	
   

  
	
   

  	
  (signed by
  respective executives)

  	
   

  	
   

  
	
  [NAME]

  
	
  [TITLE]

  
	
  Date: